Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial

Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial

Background Optimal first-line therapy for metastatic triple-negative breast cancer (mTNBC) varied in different situations. This phase II trial explores the efficacy and safety of combination regimens with bevacizumab, tislelizumab and nab-paclitaxel (BETINA) in first-line setting for mTNBC.Methods P...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wei Yang, Qi Sun, Fei Xu, Jing Peng, Cong Xue, Meiting Chen, Riqing Huang, Qixiang Rong, Xiujiao Shen, Ditian Shu, Kuikui Jiang, Xin An, Haifeng Li, Yanxia Shi
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-04-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/4/e011314.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
by: Wenjie Liu, et al.
Published: (2025-04-01)

Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
by: Elena Ferris Villanueva, et al.
Published: (2015-02-01)

Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
by: Syvart Dennen, et al.
Published: (2025-08-01)

Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuropathy: a cross-sectional cohort study
by: Terry Trinh, et al.
Published: (2025-04-01)

A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancerResearch in context
by: Qiang Wen, et al.
Published: (2025-07-01)

Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas
by: Jinpeng Li, et al.
Published: (2025-08-01)

Baseline differences in metabolic profiles of patients with lung squamous cell carcinoma responding or not responding to treatment with nanoparticle albumin-bound paclitaxel (nab-paclitaxel)
by: Peng Cao, et al.
Published: (2023-08-01)

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis
by: J. Ventriglia, et al.
Published: (2018-01-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer in China
by: Yibing Hou, et al.
Published: (2025-08-01)

Physicochemical Stability of Nab-Paclitaxel (Pazenir) Infusion Dispersions in Original Glass Vials and EVA Infusion Bags
by: Helen Linxweiler, et al.
Published: (2024-10-01)

Correction: Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas
by: Jinpeng Li, et al.
Published: (2025-08-01)

ABCG2 protein expression in tumors of patients with non-resectable pancreatic cancer treated with gemcitabine and nab-paclitaxel
by: Susy Shim, et al.
Published: (2025-06-01)

The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study
by: Andreas Schneeweiss, et al.
Published: (2025-06-01)

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma
by: Shuhang Wang, et al.
Published: (2020-05-01)

Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study
by: Yunjie Huang, et al.
Published: (2025-07-01)

Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer
by: Rakesh Bhatia, et al.
Published: (2025-08-01)

Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion
by: Carlos Sergio Rocha Silva, et al.
Published: (2025-08-01)

CHARACTERISTICS OF RENIN PROFILE AND PARAMETERS OF ARTERIAL STIFFNESS IN PATIENTS WITH PREVIOUSLY UNTREATED HYPERTENSION
by: O. A. Kravtsova, et al.
Published: (2015-09-01)

GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone as first-line treatment for metastatic pancreatic cancer
by: Sophie Gourgou, et al.
Published: (2025-08-01)

Weekly paclitaxel in escalating doses in a patient with anthracycline-resistant, triple-negative, metastatic breast cancer with severe liver dysfunction
by: Ajay Gupta
Published: (2012-01-01)

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma
by: Kunyuan Wang, et al.
Published: (2025-06-01)

GPRC5A/CXCL8/NLRP3-mediated neutrophil extracellular traps drive gemcitabine-nab-paclitaxel resistance in pancreatic adenocarcinoma
by: Tianyi Zhu, et al.
Published: (2025-07-01)

PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study
by: Riqing Huang, et al.
Published: (2025-03-01)

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
by: Hongjie Cai, et al.
Published: (2025-02-01)

Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclitaxel therapy
by: M. Sugimori, et al.
Published: (2025-09-01)

Clinical case use bevacizumab for patient with metastatic ovarian cancer
by: M. R. Oganyan, et al.
Published: (2014-07-01)

Phase I clinical trial to assess safety and efficacy of Oraxol, a novel oral paclitaxel chemotherapy agent, in patients with previously treated metastatic breast cancer
by: Yunfang Yu, et al.
Published: (2025-03-01)

Predictive analysis of all-cause mortality of previously untreated pulmonary tuberculosis patients complicated by hypertension
by: Anhua Cao, et al.
Published: (2025-08-01)

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
by: Gabriel Capellá, et al.
Published: (2022-03-01)

Safety and efficacy of generic nab-paclitaxel-based therapy in Chinese patients with malignant tumors in a real-world setting: a multicenter prospective observational study
by: Fei He, et al.
Published: (2024-11-01)

Polymeric Micellar Paclitaxel Plus Cisplatin Combined With Tislelizumab as the First‐Line Treatment of Advanced Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study
by: Xiaoyou Li, et al.
Published: (2025-04-01)

Impact of pathological complete response following neoadjuvant chemotherapy (gemcitabine, nab-paclitaxel, S-1) and radiation for borderline resectable pancreatic cancer: a case report and review of literature
by: Mitsuru Kinoshita, et al.
Published: (2022-09-01)

Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study
by: Serhat Sekmek, et al.
Published: (2024-11-01)

Soluble Epoxide Hydrolase Inhibitor TPPU Alleviates Nab-Paclitaxel-Induced Peripheral Neuropathic Pain via Suppressing NF-κB Signalling in the Spinal Cord of a Rat
by: Xing Wei, et al.
Published: (2023-01-01)

Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial
by: Xiao Yang, et al.
Published: (2025-08-01)

Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial
by: Zhigang Liu, et al.
Published: (2025-05-01)

De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trialResearch in context
by: Hong Pan, et al.
Published: (2025-08-01)

Natural history and prognostic nomogram of untreated triple negative breast cancer based on SEER database
by: Dasong Wang, et al.
Published: (2025-07-01)

Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
by: Toshiaki Takahashi, et al.
Published: (2025-01-01)

Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report
by: Takahiro Murokawa, et al.
Published: (2022-02-01)